Moderna and Merck mRNA Vaccine Shows Breakthrough in Melanoma Trial

Moderna and Merck have announced positive late-stage trial results for a personalized mRNA melanoma vaccine, demonstrating that the treatment significantly reduces cancer recurrence and spread when used alongside the immunotherapy drug Keytruda. The findings mark the first successful late-stage trial for an mRNA cancer vaccine and represent a potential turning point in the treatment of solid tumors, with the therapy potentially reaching patients as early as next year if regulators give their approval.

The vaccine is custom-built for each patient. After a tumor is surgically removed, Moderna analyzes the specific mutations present in that patient’s cancer cells. Using mRNA technology, the company manufactures a vaccine designed to train the patient’s immune system to recognize and attack cells bearing those exact mutations. The trial enrolled 1,137 high-risk patients with stage IIB through stage IV melanoma whose tumors had been surgically excised. Participants were randomized to receive either Keytruda plus the personalized vaccine or Keytruda alone over approximately one year. The companies reported that no new safety signals emerged during the trial.

These results build on earlier mid-stage findings released in January, which showed that the combination therapy reduced the risk of recurrence or death by 49 percent after five years. The mechanism is worth noting: Keytruda, a checkpoint inhibitor, broadly removes brakes from the immune system, while the mRNA vaccine provides a targeted instruction manual for what to attack. The combination appears to be more effective than either approach alone, and this trial is the first to demonstrate that adding a treatment to Keytruda improved outcomes over Keytruda monotherapy. Similar personalized mRNA approaches are now being tested against lung, breast, and pancreatic cancers.

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, described the results as the beginning of a new phase in immunotherapy for solid tumors. The market reacted sharply: Moderna’s shares more than doubled on the news, adding roughly $30 billion to the company’s market capitalization. That valuation reflects both the commercial potential of the melanoma treatment and the broader signal that mRNA technology may finally deliver on its promise beyond infectious disease vaccines.

However, significant questions remain. Each vaccine must be individually manufactured based on a patient’s tumor sequencing, which limits economies of scale and will likely keep costs high. Keytruda alone carries a list price around $200,000 per course, and analysts expect the vaccine to be priced similarly. Access and reimbursement will be critical hurdles. Political factors could also complicate adoption, given ongoing skepticism toward mRNA technology in some segments of the population and within federal health agencies. Whether regulators and policymakers treat this as a standard cancer therapy or as a politicized vaccine will influence how quickly patients can benefit.

The broader implication is that mRNA platforms, originally validated during the pandemic, may now transform oncology treatment. If subsequent trials in other cancer types produce similar results, the technology could reshape standard of care for multiple solid tumors. For now, the melanoma data provide the strongest evidence yet that personalized mRNA vaccines have a role to play in treating cancer, not just preventing infectious disease.